MHRA consults on draft guidance on randomised controlled trials generating real-world evidence to support regulatory decisions

Draft guidance provides points to consider when planning a randomised clinical trial using real world data, with the intention of submitting this trial to gain a regulatory approval - such as extending the use of a medication into a new indication or a broader patient population.

Source:

Medicines and Healthcare products Regulatory Agency